The results of the PRADA trial showed that concomitant candesartan treatment in early-stage HER2-postive BC patients treated with anthracycline-based adjuvant chemotherapy with sequential trastuzumab was effective in reversing the early decline in LVEF. This evidence concerns the gene ERBB2 and breast cancer.